Predictive Diagnostics Market (2021 - 2031)
Predictive Diagnostics Market By Test (PCR based, NGS (sequencing) based), By Indication (Cancer, Metabolic Disorders, Neurological Disorders, Musculoskeletal Diseases), By End User, By Region - Global Market Insights 2021 to 2031
Core Findings
FREE CustomizationPredictive Diagnostics Market Outlook
The healthcare industry is constantly under the pressure of improving patient care while keeping the costs under a certain limit. Predictive diagnostics is one way for healthcare organizations to achieve success at enhanced outcomes at much lower costs.
With advancements in data-based technologies and their convergence with healthcare practices, the adoption of predictive diagnostics is expected to transform the way the healthcare industry works.
Manufacturers are incorporating advanced technologies such as Artificial Intelligence (AI), business intelligence (BI), Machine Learning (ML), and advanced data analytics to reach the highest levels of accuracy in their products.
The future of the healthcare industry is expected to be redefined by the growing adoption of predictive diagnostics, and this signals the positive growth of the predictive diagnostics market.
Insights by Test Type
Polymerase chain reaction (PCR) is one of the most popular and commonly-used categories of molecular diagnostic tests implemented as a part of various healthcare treatments.
Mainly due to the fact that PCR-based tests are highly sensitive tests with lower parasite load, they are especially relevant in chronic cutaneous lesions.
This is one of the prominent growth prospects for manufacturers of PCR-based predictive diagnostic tools. As PCR-based predictive diagnostic tests are considered among the most accurate diagnostic methods, their adoption is expected to remain significantly high in the coming years.
While the popularity of PCR-based predictive diagnostics continues to grow, the adoption of next-generation sequencing (NGS) platforms is also picking pace in the predictive diagnostics market.
The advancements in the data sequencing methodologies is expected to trigger automation in diagnostic testing, and this is also expected to boost the adoption of NSG-based predictive diagnostics among end users, setting a new trend in the market in the coming future.
Predictive Diagnostics in Cancer Detection
Key players in the predictive diagnostics market are expected to witness high revenue flows from the predictive diagnostic tools and predictive testing equipment used for the prediction of the risk of cancer.
Though cancer is not a genetic disorder, some types of cancer such as breast, ovarian cancer, and colorectal cancer can be transferred genetically.
Growing prevalence of these types of cancer is triggering patients, mainly women, to opt for predictive testing to identify their exposure to the risk of getting affected by these diseases.
Manufacturers in the predictive diagnostics market are upscaling the production as well as research & development of innovative, high-tech tools for accurately predicting the risk of cancer.
Market players are also expanding their networks beyond investors to include subject matter experts and researchers to gain a competitive edge in the segment.
In the coming years, along with cancer, manufacturers are expected to increase focus on introducing predictive diagnostic tools for neurological and metabolic disorders to diversify their product offerings.
Predictive Diagnostics Market by End User
The adoption of predictive diagnostics is significantly high in various healthcare organizations including diagnostic centers, genetic laboratories and clinics, and research and academic institutes.
Growing awareness about predictive diagnostics across these end user segments is expected to drive the growth of the market.
The demand for predictive diagnostic tools is expected to remain significantly high in diagnostic centers, as the end users segment is rapidly moving towards adopting the trend of predictive medicine and precision treatment.
A mounting number of diagnostic labs are expected to set an aim of using sophisticated technologies in diagnostics to boost the use of precision medicine treatment and testing in order to dramatically enhance patient care.
Healthcare service providers are seeking diagnostic tools to predict how patients will react to medications and based on which, a proper treatment can be planned for improving patient outcomes.
Genetic laboratories are also expected to utilize predictive diagnostics to add innovative clinical services by creating digital decision support through such high-tech tools for improved clinical care at controlled costs.
Regional Outlook on Predictive Diagnostics Market
The adoption of predictive diagnostic equipment is significantly high in US and Europe, mainly attributing to the increasing integration of technologies in the healthcare industry.
Significant presence of global players in the region also makes North America a leaving market for predictive diagnostics. Market leaders are also collaborating to discover novel disease triggers through the use of next-generation technologies and develop therapies for effective treatment.
This is expected to further bolster the growth of the North America predictive diagnostics market.
Along with North America, Asia Pacific is also emerging as a profitable region for players in the global predictive diagnostics market.
A significant surge in healthcare spending and growing customer awareness about health and wellbeing is expected to create new opportunities for predictive diagnostic tools in the region.
Prominent players in the market are tapping into the regional opportunities by expanding their presence in developing economies through their distribution partners.
Key Players
Key players in the global predictive diagnostics market are Abbott Laboratories, Therawis, F.Hoffmann-La Roche Ltd., BIOMÉRIEUX SA, Agilent Technologies, Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad, Myriad Genetics, Inc., Genesis Genetics, Centogene N.V., BGI, 23andMe, Inc., Predictive Oncology, Counsyl, Inc., Bio-Rad Laboratories Inc., Mylab Discovery Solutions Pvt. Ltd., and ARUP Laboratories.
In September 2021, Janssen - a pharmaceutical subsidiary of Johnson & Johnson - announced that it has introduced its nine-month startup accelerator - a program for the digital health startup space to gain innovative ideas on predictive diagnostics to discover precision treatment and therapies.
With this step, the company aims to introduce digital tools to facilitate clinical trials in different disease areas, ultimately to discover treatments at much lower costs.
Through this program, the company will provide selected startups from the Europe, Middle East and Africa (EMEA) region with nine months of support as well as mentorship with members iPEPS - a French brain health incubator - and Janssen.
In October 2021, bioMérieux - a French multinational biotechnology company and a world leader in the area of in-vitro diagnostics - announced that it has launched predictive Diagnostics, which is the company’s new offering in the field of food safety and food quality.
The company’s Predictive Diagnostics offering combines traditional solutions vis-a-vis core microbiology with advanced technologies such as predictive modeling, data sequencing, and data science, declared the global R&D director - Food at bioMérieux.
The Analyst’s Viewpoint
“Advancements in data-based technologies, data science, and data analytics formulates the base for the flourishing market for predictive diagnostics.
Manufacturers must, rather than simply recording crucial data, offer new insights, value, and action points for the treatment or therapies for avoiding impending health disorders", opines a lead analyst at Fact.MR
Rising prevalence of lifestyle diseases has bolstered the public awareness to make people health conscious. This is further triggering the adoption of predictive diagnostics. Market players will have to introduce convenient and simpler diagnostic tools that can help doctors as well as patients to gain access to precision treatment quickly.
About the Report
Fact.MR has published a detailed and well-researched study on the growth projections of the predictive diagnostics market during the forecast period of 2021 to 2031.
The report includes analytics based on thorough studies about various factors that may boost or hinder the growth of the market in the coming years.
The report also highlights potential for growth and opportunities for all the stakeholders in the predictive diagnostics market during 2021 and 2031.
The team of seasoned analysts at Fact.MR has analyzed a wide range of growth parameters and derived actionable insights for market players to register astonishing growth in the predictive diagnostics market.
The unique recommendations and conclusions in the Fact.MR report can help stakeholders to plan their upcoming strategies to fetch remarkable profits in the predictive diagnostics market in the coming years.
The report also includes detailed regional insights about how the predictive diagnostics market will grow in various geographical areas and which factors will influence the growth prospects for local players.
This can further give market players a clear idea about the competitive landscape in the global as well as regional predictive diagnostics market.
Predictive Diagnostics Market: Segmentation
The study offers a detailed estimation and outlook of the predictive diagnostics market based on the test, indication, end user, and region.
-
By Test :
- PCR based
- NGS (sequencing) based
-
By Indication :
- Cancer
- Metabolic Disorders
- Neurological Disorders
- Musculoskeletal Diseases
- Others
-
By End User :
- Diagnostics
- Genetic Laboratories And Clinics
- Research And Academic Institutes
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Market Background
- 5. Market Context
- 6. Global Value Analysis 2016 to 2020 and Forecast, 2021 to 2031
- 7. Global Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
- 7.1. PCR based
- 7.2. NGS (sequencing) based
- 8. Global Analysis 2016 to 2020 and Forecast 2021 to 2031, by Indication
- 8.1. Cancer
- 8.2. Metabolic disorders
- 8.3. Neurological disorders
- 8.4. Musculoskeletal diseases
- 8.5. Others
- 9. Global Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
- 9.1. Diagnostics
- 9.2. Genetic Laboratories And Clinics
- 9.3. Research And Academic Institutes
- 10. Global Analysis 2016 to 2020 and Forecast 2021 to 2031, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Europe
- 10.4. East Asia
- 10.5. South Asia
- 10.6. Oceania
- 10.7. Middle East and Africa (MEA)
- 11. North America Analysis 2016 to 2020 and Forecast 2021 to 2031
- 12. Latin America Analysis 2016 to 2020 and Forecast 2021 to 2031
- 13. Europe Analysis 2016 to 2020 and Forecast 2021 to 2031
- 14. South Asia Analysis 2016 to 2020 and Forecast 2021 to 2031
- 15. East Asia Analysis 2016 to 2020 and Forecast 2021 to 2031
- 16. Oceania Analysis 2016 to 2020 and Forecast 2021 to 2031
- 17. Middle East and Africa Analysis 2016 to 2020 and Forecast 2021 to 2031
- 18. Key and Emerging Countries Analysis 2016 to 2020 and Forecast 2021 to 2031
- 19. Market Structure Analysis
- 20. Competition Analysis
- 20.1. Qiagen
- 20.2. Therawis
- 20.3. Myriad Genetics, Inc.
- 20.4. BIOMÉRIEUX SA
- 20.5. Hoffmann-La Roche
- 20.6. Thermo Fisher Scientific
- 20.7. Bio-Rad
- 20.8. Centogene N.V.
- 20.9. Predictive Oncology
- 20.10. Mylab Discovery Solutions Pvt. Ltd.
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
List Of Table
Table 01: Global Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Table 02: Global Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 03: Global Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Table 04: Global Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Region
Table 05: North America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 06: North America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Table 07: North America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 08: North America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Table 09: Latin America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 10: Latin America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Table 11: Latin America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 12: Latin America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Table 13: Europe Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 14: Europe Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Table 15: Europe Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 16: Europe Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Table 17: East Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 18: East Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Table 19: East Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 20: East Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Table 21: South Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 22: South Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Table 23: South Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 24: South Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Table 25: Oceania Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 26: Oceania Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Table 27: Oceania Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 28: Oceania Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Table 29: MEA Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 30: MEA Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Table 31: MEA Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 32: MEA Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
List Of Figures
Figure 01: Global Size (US$ Mn) Analysis, 2016 to 2020
Figure 02: Global Size (US$ Mn) & Y-o-Y Growth (%) Analysis, 2021 to 2031
Figure 03: Global Absolute $ Opportunity Analysis, 2021 to 2031
Figure 04: Global Analysis by Test Type to 2021 & 2031
Figure 05: Global Y-o-Y Growth Projections by Test Type, 2021 to 2031
Figure 06: Global Attractiveness Analysis By Test Type, 2021 to 2031
Figure 07: Global Analysis by Indication to 2021 & 2031
Figure 08: Global Y-o-Y Growth Projections by Indication, 2021 to 2031
Figure 09: Global Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Indication
Figure 10: Global Analysis by End User to 2021 & 2031
Figure 11: Global Y-o-Y Growth Projections by End User , 2021 to 2031
Figure 12: Global Attractiveness Analysis 2021 to 2031, By End User
Figure 13: Global Share Analysis (%) By Region, 2021 & 2031
Figure 14: Global Y-o-Y Growth (%) By Region, 2021 to 2031
Figure 15: Global Attractiveness Analysis 2021 to 2031, By Region
Figure 16: North America Size (US$ Mn) Analysis, 2016 to 2020
Figure 17: North America Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 18: North America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Country
Figure 19: North America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Figure 20: North America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, Indication
Figure 21: North America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Figure 22: Latin America Size (US$ Mn) Analysis, 2016 to 2020
Figure 23: Latin America Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 24: Latin America Medical America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Country
Figure 25: Latin America Medical America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Figure 26: Latin America Medical America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, Indication
Figure 27: Latin America Medical America Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Figure 28: Europe Size (US$ Mn) Analysis, 2016 to 2020
Figure 29: Europe Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 30: Europe Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Country
Figure 31: Europe Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Figure 32: Europe Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, Indication
Figure 33: Europe Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Figure 34: East Asia Size (US$ Mn) Analysis, 2016 to 2020
Figure 35: East Asia Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 36: East Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Country
Figure 37: East Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Figure 38: East Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, Indication
Figure 39: East Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Figure 40: South Asia Size (US$ Mn) Analysis, 2016 to 2020
Figure 41: South Asia Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 42: South Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Country
Figure 43: South Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Figure 44: South Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, Indication
Figure 45: South Asia Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Figure 46: Oceania Size (US$ Mn) Analysis, 2016 to 2020
Figure 47: Oceania Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 48: Oceania Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Country
Figure 49: Oceania Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Figure 50: Oceania Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, Indication
Figure 51: Oceania Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Figure 52: MEA Size (US$ Mn) Analysis, 2016 to 2020
Figure 53: MEA Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 54: MEA Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Country
Figure 55: MEA Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by Test Type
Figure 56: MEA Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, Indication
Figure 57: MEA Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, by End User
Figure 58: China Market Value Proportion Analysis, 2021
Figure 59: China Share Analysis (%) By Test Type, 2021 & 2031
Figure 60: China. Share Analysis (%) By Indication, 2021 & 2031
Figure 61: China. Share Analysis (%) By End User, 2021 & 2031
Figure 62: Global Vs. China Growth Comparison
Figure 63: India Market Value Proportion Analysis, 2021
Figure 64: India. Share Analysis (%) By Test Type, 2021 & 2031
Figure 65: India. Share Analysis (%) By Indication, 2021 & 2031
Figure 66: India. Share Analysis (%) By End User, 2021 & 2031
Figure 67: Global Vs. India Growth Comparison
Figure 68: Brazil Market Value Proportion Analysis, 2021
Figure 69: Brazil. Share Analysis (%) By Test Type, 2021 & 2031
Figure 70: Brazil. Share Analysis (%) By Indication, 2021 & 2031
Figure 71: Brazil. Share Analysis (%) By End User, 2021 & 2031
Figure 72: Global Vs. Brazil Growth Comparison
Figure 73: U.S Market Value Proportion Analysis, 2021
Figure 74: U.S. Share Analysis (%) By Test Type, 2021 & 2031
Figure 75: U.S. Share Analysis (%) By Indication, 2021 & 2031
Figure 76: U.S. Share Analysis (%) By End User, 2021 & 2031
Figure 77: Global Vs. U.S Growth Comparison
Figure 78: Canada Market Value Proportion Analysis, 2021
Figure 79: Canada Share Analysis (%) By Test Type, 2021 & 2031
Figure 80: Canada Share Analysis (%) By Indication, 2021 & 2031
Figure 81: Canada Share Analysis (%) By End User, 2021 & 2031
Figure 82: Global Vs. Canada Growth Comparison
Figure 83: Mexico Market Value Proportion Analysis, 2021
Figure 84: Mexico Share Analysis (%) By Test Type, 2021 & 2031
Figure 85: Mexico Share Analysis (%) By Indication, 2021 & 2031
Figure 86: Mexico Share Analysis (%) By End User, 2021 & 2031
Figure 87: Global Vs. Mexico Growth Comparison
Figure 88: Argentina Market Value Proportion Analysis, 2021
Figure 89: Argentina Share Analysis (%) By Test Type, 2021 & 2031
Figure 90: Argentina Share Analysis (%) By Indication, 2021 & 2031
Figure 91: Argentina Share Analysis (%) By End User, 2021 & 2031
Figure 92: Global Vs. Argentina Growth Comparison
Figure 93: U.K. Market Value Proportion Analysis, 2021
Figure 94: U.K. Share Analysis (%) By Test Type, 2021 & 2031
Figure 95: U.K. Share Analysis (%) By Indication, 2021 & 2031
Figure 96: U.K. Share Analysis (%) By End User, 2021 & 2031
Figure 97: Global Vs. U.K Growth Comparison
Figure 98: Germany Market Value Proportion Analysis, 2021
Figure 99: Germany Share Analysis (%) By Test Type, 2021 & 2031
Figure 100: Germany Share Analysis (%) By Indication, 2021 & 2031
Figure 101: Germany Share Analysis (%) By End User, 2021 & 2031
Figure 102: Global Vs. Germany Growth Comparison
Figure 103: France Market Value Proportion Analysis, 2021
Figure 104: France Share Analysis (%) By Test Type, 2021 & 2031
Figure 105: France Share Analysis (%) By Indication, 2021 & 2031
Figure 106: France Share Analysis (%) By End User, 2021 & 2031
Figure 107: Global Vs. France Growth Comparison
Figure 108: Italy Market Value Proportion Analysis, 2021
Figure 109: Italy Share Analysis (%) By Test Type, 2021 & 2031
Figure 110: Italy Share Analysis (%) By Indication, 2021 & 2031
Figure 111: Italy Share Analysis (%) By End User, 2021 & 2031
Figure 112: Global Vs. Italy Growth Comparison
Figure 113: Spain Market Value Proportion Analysis, 2021
Figure 114: Spain Share Analysis (%) By Test Type, 2021 & 2031
Figure 115: Spain Share Analysis (%) By Indication, 2021 & 2031
Figure 116: Spain Share Analysis (%) By End User, 2021 & 2031
Figure 117: Global Vs. Spain Growth Comparison
Figure 118: Russia Market Value Proportion Analysis, 2021
Figure 119: Russia Share Analysis (%) By Test Type, 2021 & 2031
Figure 120: Russia Share Analysis (%) By Indication, 2021 & 2031
Figure 121: Russia Share Analysis (%) By End User, 2021 & 2031
Figure 122: Global Vs. Russia Growth Comparison
Figure 123: Japan Market Value Proportion Analysis, 2021
Figure 124: Japan Share Analysis (%) By Test Type, 2021 & 2031
Figure 125: Japan Share Analysis (%) By Indication, 2021 & 2031
Figure 126: Japan Share Analysis (%) By End User, 2021 & 2031
Figure 127: Global Vs. Japan Growth Comparison
Figure 128: South Korea Market Value Proportion Analysis, 2021
Figure 129: South Korea Share Analysis (%) By Test Type, 2021 & 2031
Figure 130: South Korea Share Analysis (%) By Indication, 2021 & 2031
Figure 131: South Korea Share Analysis (%) By End User, 2021 & 2031
Figure 132: Global Vs. South Korea Growth Comparison
Figure 133: Indonesia Market Value Proportion Analysis, 2021
Figure 134: Indonesia Share Analysis (%) By Test Type, 2021 & 2031
Figure 135: Indonesia Share Analysis (%) By Indication, 2021 & 2031
Figure 136: Indonesia Share Analysis (%) By End User, 2021 & 2031
Figure 137: Global Vs. Indonesia Growth Comparison
Figure 138: Malaysia Market Value Proportion Analysis, 2021
Figure 139: Malaysia Share Analysis (%) By Test Type, 2021 & 2031
Figure 140: Malaysia Share Analysis (%) By Indication, 2021 & 2031
Figure 141: Malaysia Share Analysis (%) By End User, 2021 & 2031
Figure 142: Global Vs. Malaysia Growth Comparison
Figure 143: Thailand Market Value Proportion Analysis, 2021
Figure 144: Thailand Share Analysis (%) By Test Type, 2021 & 2031
Figure 145: Thailand Share Analysis (%) By Indication, 2021 & 2031
Figure 146: Thailand Share Analysis (%) By End User, 2021 & 2031
Figure 147: Global Vs. Thailand Growth Comparison
Figure 148: Australia Market Value Proportion Analysis, 2021
Figure 149: Australia Share Analysis (%) By Test Type, 2021 & 2031
Figure 150: Australia Share Analysis (%) By Indication, 2021 & 2031
Figure 151: Australia Share Analysis (%) By End User, 2021 & 2031
Figure 152: Global Vs. Australia Growth Comparison
Figure 153: New Zealand Market Value Proportion Analysis, 2021
Figure 154: New Zealand Share Analysis (%) By Test Type, 2021 & 2031
Figure 155: New Zealand Share Analysis (%) By Indication, 2021 & 2031
Figure 156: New Zealand Share Analysis (%) By End User, 2021 & 2031
Figure 157: Global Vs. New Zealand Growth Comparison
Figure 158: South Africa Market Value Proportion Analysis, 2021
Figure 159: South Africa Share Analysis (%) By Test Type, 2021 & 2031
Figure 160: South Africa Share Analysis (%) By Indication, 2021 & 2031
Figure 161: South Africa Share Analysis (%) By End User, 2021 & 2031
Figure 162: Global Vs. South Africa Growth Comparison
Figure 163: GCC Countries Market Value Proportion Analysis, 2021
Figure 164: GCC Countries Share Analysis (%) By Test Type, 2021 & 2031
Figure 165: GCC Countries Share Analysis (%) By Indication, 2021 & 2031
Figure 166: GCC Countries Share Analysis (%) By End User, 2021 & 2031
Figure 167: Global Vs. GCC Countries Growth Comparison
- FAQs -
Which region will act as major contributor of Predictive Diagnostics Market?
The adoption of predictive diagnostic equipment is significantly high in US and Europe.
Related Reports
Predictive Diagnostics Market